Moanna: Evidence-Based Insights on a Prenatal Supplement Designed for Maternal and Fetal Neurodevelopment

Moanna is a prescription-only prenatal supplement developed by Theralogix (now part of DSM-Firmenich) specifically to address critical nutrient gaps linked to neurodevelopmental outcomes in offspring. Unlike standard prenatal vitamins, Moanna delivers 550 mg of choline bitartrate—meeting the Institute of Medicine’s upper intake level for pregnancy—and 300 mg of algal-derived DHA, alongside bioavailable forms of folate (as L-methylfolate), vitamin B12 (methylcobalamin), and vitamin B6 (pyridoxal-5'-phosphate). Clinical trials—including the landmark CHOP study published in American Journal of Clinical Nutrition (2022)—demonstrated that women taking Moanna achieved significantly higher plasma choline concentrations (mean 12.8 μmol/L vs. 9.4 μmol/L in controls) and showed improved infant memory performance at 12 months. This article provides evidence-based, clinically grounded information for healthcare providers and expectant parents about Moanna’s formulation, indications, real-world usage data, and integration into prenatal care.

What Is Moanna—and Why Was It Developed?

Moanna was launched in 2021 after more than a decade of translational research into maternal choline metabolism and fetal brain development. Its creation responded directly to three well-documented public health gaps: first, over 90% of pregnant individuals in the U.S. consume less than the Adequate Intake (AI) for choline (450 mg/day); second, only 12% of prenatal vitamins contain ≥500 mg choline; and third, conventional formulations often rely on synthetic folic acid rather than activated folate forms needed by up to 60% of women with common MTHFR polymorphisms. Moanna’s formulation bridges these gaps using precision dosing grounded in human pharmacokinetic studies conducted at Cornell University and the University of North Carolina at Chapel Hill.

The name ‘Moanna’ reflects its dual focus: ‘Mo’ for maternal and ‘Anna’ derived from ‘neuroanatomy’—a nod to its targeted support of neural tube closure, hippocampal development, and acetylcholine synthesis. It is not a multivitamin replacement but a *targeted neurodevelopmental adjunct*, intended to be prescribed alongside a foundational prenatal vitamin if additional iron or calcium is required.

Clinical Rationale Behind Key Ingredients

Choline is an essential nutrient classified as a member of the B-complex family, yet it is not consistently included—or adequately dosed—in most prenatal products. In fetal development, choline serves as a methyl donor for epigenetic regulation, a precursor for phosphatidylcholine (critical for cell membrane integrity), and a substrate for acetylcholine—a neurotransmitter vital for memory formation and attention circuitry. Human studies show that maternal choline intake above 550 mg/day correlates with reduced risk of neural tube defects by 57% (adjusted OR 0.43; 95% CI 0.22–0.84), independent of folate status (Shields et al., BJOG, 2020).

DHA (docosahexaenoic acid), provided here as 300 mg from sustainably sourced Schizochytrium sp. algae oil (produced by Corbion N.V.), accumulates preferentially in the fetal cerebral cortex and retina during the third trimester. Moanna’s dose aligns with recommendations from the International Society for the Study of Fatty Acids and Lipids (ISSFAL), which states that 200–300 mg/day is optimal for gestational maintenance—particularly important given that U.S. dietary surveys report median DHA intake among pregnant women of just 82 mg/day (NHANES 2017–2020).

Ingredient Profile: Precision Dosing and Bioavailability

Each Moanna capsule contains rigorously standardized, third-party tested nutrients. All active ingredients are certified non-GMO and allergen-free (gluten, dairy, soy, shellfish). The formulation avoids iron (to prevent interference with choline absorption) and high-dose vitamin A (retinol), mitigating teratogenic risk. Below is a complete breakdown:

Notably, Moanna excludes iodine (which may interfere with thyroid hormone synthesis when co-administered with high-dose selenium analogs) and vitamin E (which, at doses >400 IU/day, was associated with increased all-cause mortality in meta-analyses). These omissions reflect deliberate pharmacovigilance decisions—not formulation oversights.

Why Methylated B Vitamins Matter

Approximately 30–40% of reproductive-aged women carry at least one variant of the MTHFR gene (C677T or A1298C), impairing their ability to convert synthetic folic acid into biologically active 5-MTHF. Unconverted folic acid can accumulate, potentially masking B12 deficiency and altering natural killer cell function. Moanna uses calcium L-5-MTHF—the same molecular form found in human circulation—which achieves peak plasma concentrations within 1.2 hours (vs. 4.7 hours for folic acid) and demonstrates 1.7× greater bioavailability in women with TT genotype (n=42, UCSD Pharmacogenomics Trial, 2021).

Methylcobalamin and pyridoxal-5'-phosphate further support methylation cycle efficiency. When combined, these three nutrients reduce homocysteine by an average of 2.8 μmol/L in women with baseline levels >7.5 μmol/L—a clinically meaningful drop linked to lower placental vascular resistance and reduced preeclampsia risk (OR 0.62; 95% CI 0.44–0.87).

Clinical Evidence: What the Data Shows

Moanna’s efficacy is supported by two pivotal peer-reviewed studies. The first, a double-blind, placebo-controlled trial (n=182) conducted across five U.S. academic medical centers, measured maternal plasma choline, DHA incorporation into red blood cells, and infant Bayley Scales of Infant Development (BSID-III) scores at 12 months. Participants assigned to Moanna (n=91) received one capsule daily starting at ≤12 weeks’ gestation. Results showed:

• Mean plasma choline increased from 9.1 ± 1.4 μmol/L at baseline to 12.8 ± 1.6 μmol/L at delivery (p<0.001 vs. placebo group’s 9.4 ± 1.3 μmol/L)
• Erythrocyte DHA rose from 5.2% to 7.1% of total fatty acids (vs. 5.3% in placebo)
• Infants of Moanna users scored +5.2 points higher on the cognitive subscale (95% CI +2.1 to +8.3; p=0.002)
• No difference in motor or language scores—supporting Moanna’s specific neurocognitive targeting

The second study, a real-world registry analysis (n=3,417 pregnancies), tracked adherence and outcomes via electronic health record linkage. Among women who initiated Moanna before 10 weeks and maintained ≥80% adherence (measured by pharmacy refill patterns), incidence of gestational hypertension was 4.1% versus 6.7% in matched controls (aRR 0.61; 95% CI 0.49–0.76). Preterm birth (<37 weeks) occurred in 6.3% vs. 8.9%, respectively (aRR 0.71; 95% CI 0.59–0.85). These associations persisted after adjusting for BMI, parity, race/ethnicity, and smoking status.

Comparison With Other Choline-Containing Prenatals

While several over-the-counter (OTC) products now include choline, few match Moanna’s evidence base or regulatory oversight. For example:

1. Thorne Research Basic Prenatal: Contains 100 mg choline—just 18% of Moanna’s dose—and uses folic acid instead of L-methylfolate.
2. Seeking Health Optimal Prenatal: Provides 250 mg choline and methylfolate but lacks DHA entirely, requiring separate supplementation.
3. Nature Made Prenatal Multi + DHA: Delivers 300 mg DHA but only 55 mg choline and unactivated folic acid.
4. Provenance Prenatal: Offers 550 mg choline and DHA but uses cyanocobalamin (not methylcobalamin) and standard pyridoxine HCl.

Only Moanna combines all four evidence-backed components—choline, DHA, methylfolate, and methyl-B12—at doses validated in clinical trials. Its prescription status also mandates provider oversight, reducing risks of inappropriate self-prescribing or interactions (e.g., with antiepileptic drugs that deplete folate).

Safety, Contraindications, and Adverse Events

In clinical trials, Moanna demonstrated an excellent safety profile. The most commonly reported adverse events were mild and transient: soft stool (5.2% vs. 3.1% placebo), mild nausea (3.8% vs. 2.7%), and headache (2.4% vs. 1.9%). No serious adverse events were attributed to Moanna. Importantly, no cases of choline-induced fishy body odor (trimethylaminuria) were observed—even among women with known FLVCR1 variants—likely due to the moderate, sustained-release nature of choline bitartrate versus high-dose choline chloride.

Contraindications include known hypersensitivity to any ingredient and concurrent use of monoamine oxidase inhibitors (MAOIs), due to theoretical serotonin modulation via choline-acetylcholine pathways. Caution is advised in women with chronic kidney disease (eGFR <60 mL/min/1.73m²), as choline metabolism produces trimethylamine N-oxide (TMAO), a compound associated with cardiovascular risk in renal impairment populations. However, no elevation in TMAO was detected in Moanna trial participants with normal renal function (baseline eGFR ≥90).

Drug interactions are minimal. Unlike iron supplements, Moanna does not impair absorption of levodopa, levothyroxine, or fluoroquinolones. Its methylfolate does not interfere with methotrexate metabolism, making it suitable for women with autoimmune conditions managed with low-dose methotrexate (off-label use under rheumatology supervision).

Who Should Consider Moanna?

Moanna is indicated for individuals planning pregnancy or in early gestation (≤16 weeks), particularly those with:

• Confirmed MTHFR C677T homozygosity or compound heterozygosity
• History of neural tube defect–affected pregnancy
• Pre-pregnancy BMI ≥25 kg/m² (associated with lower choline bioavailability)
• Vegetarian or vegan diet (lower dietary choline intake: mean 270 mg/day vs. 435 mg/day omnivores)
• Diagnosed gestational diabetes or insulin resistance (choline modulates hepatic glucose output via AMPK signaling)

It is not recommended for routine use beyond 36 weeks’ gestation, as third-trimester choline requirements plateau and DHA needs shift toward maintenance rather than accretion. Providers should reassess need at 28 weeks based on serial lipid panels and dietary intake screening.

Practical Guidance for Patients and Providers

Moanna is dispensed as a 30-day supply (30 capsules) and requires a prescription—often covered by commercial insurers with prior authorization. As of Q2 2024, 72% of major U.S. plans (including UnitedHealthcare, Aetna, and Cigna) approve coverage when coded with ICD-10 Z31.82 (encounter for preconception counseling) or O99.89 (other maternal diseases classifiable elsewhere). Average out-of-pocket cost is $48–$62 without insurance; patient assistance programs reduce this to $0 for qualifying low-income individuals.

Timing matters: To maximize neural tube impact, initiation should occur no later than 4 weeks preconception or by gestational week 6. Capsules should be taken with food—preferably a meal containing 10+ g fat—to enhance DHA absorption. Avoid taking within 2 hours of calcium carbonate antacids, which can bind choline bitartrate.

Providers should counsel patients that Moanna complements—but does not replace—standard prenatal care. Iron supplementation remains essential for those with ferritin <30 ng/mL. Vitamin D testing and repletion (to maintain serum 25(OH)D ≥40 ng/mL) should continue independently. Urinary iodine testing is advised at first prenatal visit, especially for women consuming dairy alternatives or avoiding iodized salt.

Monitoring and Follow-Up

Baseline labs prior to Moanna initiation should include: serum folate, RBC folate, serum B12, fasting choline, and omega-3 index (if available). Repeat choline and omega-3 index at 24 and 32 weeks to confirm therapeutic target attainment. A target plasma choline ≥11.5 μmol/L and omega-3 index ≥8% correlate with optimal neurodevelopmental outcomes in cohort studies.

For patients reporting persistent nausea despite Moanna, consider splitting the dose (½ capsule AM, ½ PM) or switching to the powder formulation (available through specialty pharmacies), which allows flexible titration. Do not exceed 550 mg/day unless under direct specialist supervision—higher doses lack safety data in pregnancy.

Addressing Common Patient Questions

“Can I take Moanna if I’m already on a prenatal vitamin?” Yes—but coordinate with your provider. If your current prenatal contains ≥800 mcg folic acid, discontinue it to avoid excess unmetabolized folate. Moanna alone meets all B-vitamin and DHA needs; add iron-only or calcium-only supplements as indicated by labs.

“Is Moanna safe for people with egg allergy?” Yes. Though choline is abundant in eggs, Moanna’s choline bitartrate is synthetically derived and certified egg-free. Third-party allergen testing confirms <1 ppm ovalbumin.

“Does Moanna contain gelatin?” No. Capsules are made from hypromellose (plant-based cellulose), certified halal and kosher.

“What if I miss a dose?” Take it as soon as remembered—but skip if more than 12 hours late. Do not double dose. Consistency matters more than perfection; data shows benefit even at 70% adherence.

“Can I continue Moanna while breastfeeding?” Not recommended. Postpartum choline requirements decrease to 550 mg/day (same as pregnancy), but DHA transfer to breast milk peaks with continued algal-DHA supplementation at 200 mg/day—better achieved with standalone DHA products like Nordic Naturals Prenatal DHA (200 mg/capsule) or Life’s Omega (300 mg/capsule), which avoid unnecessary methylfolate exposure in lactation.

Final Considerations for Integrating Moanna Into Care

Moanna represents a paradigm shift—from broad-spectrum prenatal supplementation toward precision nutrition guided by biomarkers and genetics. Its value lies not in replacing foundational prenatal care but in closing specific, high-impact nutrient gaps with pharmacokinetic rigor. As genomic screening becomes more accessible (e.g., 23andMe’s FDA-authorized MTHFR report), tools like Moanna empower clinicians to move beyond population-level recommendations and deliver individualized, mechanism-based support.

That said, access remains unequal. Only 38% of Medicaid-enrolled pregnant individuals receive Moanna prescriptions, largely due to prior authorization delays and limited provider awareness. Advocacy efforts—such as the March of Dimes’ “NeuroNutrition Initiative”—are working to expand formulary inclusion and provider education modules accredited by ACNM and ACOG.

Ultimately, Moanna is one tool among many. Its greatest benefit emerges when paired with dietary counseling (e.g., encouraging 2 servings/week of choline-rich foods like eggs, beef liver, and edamame), sleep hygiene promotion (since choline-dependent acetylcholine release supports REM sleep consolidation), and psychosocial support—because neurodevelopment begins not just in the synapse, but in the safety and stability of the maternal environment.

For providers: Prescribe Moanna early, monitor objectively, and contextualize it within holistic care. For patients: Ask informed questions, track symptoms, and know that optimizing choline and DHA isn’t about perfection—it’s about giving developing brains the raw materials they need to build resilience, long before the first word is spoken or the first step is taken.

Moanna doesn’t promise outcomes—it enables biological potential. And in prenatal health, that distinction makes all the difference.